Humacyte, Inc. short interest in 2023
In 2023, Humacyte, Inc.'s disclosed short interest ran from 4.23% of shares outstanding on 13 Jan 2023 to 5.83% on 29 Dec 2023, a change of +1.60 percentage points. The year's high was 5.88% on 15 Nov 2023 and its low 2.83% on 30 Jun 2023, averaging 4.55% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 45.66 days on 28 Apr 2023. Full history: Humacyte, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 4.23% (13 Jan 2023)
- End of year
- 5.83% (29 Dec 2023)
- Change
- +1.60 pp
- High
- 5.88% (15 Nov 2023)
- Low
- 2.83% (30 Jun 2023)
- Average
- 4.55%
- Highest days to cover
- 45.66 (28 Apr 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 4.23% | 17.90 | |
| 31 Jan 2023 | 4.35% | 23.62 | |
| 15 Feb 2023 | 4.66% | 21.36 | |
| 28 Feb 2023 | 4.83% | 13.14 | |
| 15 Mar 2023 | 4.93% | 19.91 | |
| 31 Mar 2023 | 5.09% | 25.07 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 5.04% | 34.91 | |
| 28 Apr 2023 | 5.05% | 45.66 | |
| 15 May 2023 | 5.35% | 12.88 | 10-Q filed, results (8-K) |
| 31 May 2023 | 4.18% | 11.61 | |
| 15 Jun 2023 | 2.89% | 5.13 | |
| 30 Jun 2023 | 2.83% | 3.90 | |
| 14 Jul 2023 | 2.90% | 6.64 | |
| 31 Jul 2023 | 2.91% | 8.57 | |
| 15 Aug 2023 | 3.08% | 5.05 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 3.68% | 3.81 | |
| 15 Sep 2023 | 5.08% | 5.19 | |
| 29 Sep 2023 | 5.16% | 10.06 | |
| 13 Oct 2023 | 4.93% | 14.81 | |
| 31 Oct 2023 | 5.31% | 11.56 | |
| 15 Nov 2023 | 5.88% | 8.37 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 5.66% | 20.79 | |
| 15 Dec 2023 | 5.37% | 11.87 | |
| 29 Dec 2023 | 5.83% | 16.98 |
See also: Humacyte, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.